---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-152247"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T12:18:56.352517+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics enters ATM equity distribution agreement for up to $9.8M through Piper Sandler

## Summary
- Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.
- Agent receives 3.0% commission on gross proceeds; expense reimbursement up to $75k upfront + $15k per quarter.
- Sales made under existing shelf registration (Form S-3, File 333-262551) effective Feb 2022.
- Company has no obligation to sell; may suspend or terminate the agreement at any time.
- Customary representations, warranties, and indemnification provisions included.

## SEC filing metadata
- accession: 0001193125-22-152247
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/0001193125-22-152247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/d288031d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-152247
- JSON: https://secwatch.observer/filing/0001193125-22-152247.json
- Plain text: https://secwatch.observer/filing/0001193125-22-152247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.